Merck Should Have Pulled Vioxx in 2000-Study, Reuters, 4 Nov, 2004 by Tom Armitage

 

Swiss scientists performed a meta-analysis on data obtained from Merck and the FDA. They came to the conclusion that Vioxx should have been pulled by the end of 2000. They further recommended that all future studies be carried out with independent external data evaluation. What has happened with Vioxx should raise public concern over several issues. Is the FDA being financially or otherwise compensated by the pharmaceutical industry to place drugs on the market too soon or inappropriately? When billions of dollars are at stake, is it difficult for a pharmaceutical company to evaluate the data from an objective point of view. What form of oversight should we have for this process of placing new drugs on the market? For the full article, click here.